Phylogenetic relationships, biofilm formation, motility, antibiotic resistance and extended virulence genotypes among Escherichia coli strains from women with community-onset primitive acute pyelonephritis

PloS One
Arianna PompilioGiovanni Di Bonaventura

Abstract

The present work set out to search for a virulence repertoire distinctive for Escherichia coli causing primitive acute pyelonephritis (APN). To this end, the virulence potential of 18 E. coli APN strains was genotypically and phenotypically assessed, comparatively with 19 strains causing recurrent cystitis (RC), and 16 clinically not significant (control, CO) strains. Most of the strains belong to phylogenetic group B1 (69.8%; p<0.01), and APN strains showed unique features, which are the presence of phylogroup A, and the absence of phylogroup B2 and non-typeable strains. Overall, the most dominant virulence factor genes (VFGs) were ecpA and fyuA (92.4 and 86.7%, respectively; p<0.05), and the mean number of VFGs was significantly higher in uropathogenic strains. Particularly, papAH and malX were exclusive for uropathogenic strains. APN and RC strains showed a significantly higher prevalence of fyuA, usp, and malX than of CO strains. Compared to RC strains, APN ones showed a higher prevalence of iha, but a lower prevalence of iroN, cnf1, and kpsMT-II. Hierarchical cluster analysis showed a higher proportion of two gene clusters (malX and usp, and fyuA and ecpA) were detected in the APN and RC groups than in CO, whereas iutA and...Continue Reading

References

Jul 8, 1999·International Journal of Antimicrobial Agents·K GuptaW E Stamm
Sep 30, 2000·Applied and Environmental Microbiology·O ClermontE Bingen
Dec 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·R A WelchF R Blattner
Feb 1, 2003·Annals of Epidemiology·Betsy FoxmanPatricia D Brown
Feb 20, 2004·Journal of Bacteriology·Mark A SchembriPer Klemm
Mar 12, 2004·Molecular Biology and Evolution·Patricia Escobar-PáramoErick Denamur
Jul 11, 2006·International Journal of Antimicrobial Agents·Sojun KanamaruShingo Yamamoto
Aug 9, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jaione ValleJean-Marc Ghigo
Sep 12, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S M SotoJ Vila
Oct 6, 2006·Journal of Clinical Microbiology·Maryvonne Moulin-SchouleurJorge Blanco
Mar 3, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N GrudeB-E Kristiansen
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher A CzajaWalter E Stamm
Aug 19, 2007·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Srdjan StepanovićFilip Ruzicka
Oct 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·M Chelsea LaneHarry L T Mobley
Dec 7, 2007·Journal of Bacteriology·Cheryl-Lynn Y OngMark A Schembri
Dec 14, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F RobinR Bonnet
Sep 24, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David A TalanUNKNOWN EMERGEncy ID NET Study Group
Oct 18, 2008·Journal of Medical Microbiology·Matija RijavecDarja Zgur-Bertok
Mar 31, 2009·Journal of Bacteriology·Amanda L LloydHarry L T Mobley
Apr 10, 2009·Journal of Clinical Microbiology·Dana BlackburnJorge A Girón
May 13, 2009·The Journal of Infectious Diseases·Eric L BucklesMichael S Donnenberg
Oct 7, 2009·PLoS Pathogens·Christopher J AlteriHarry L T Mobley
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Mitchell T ButlerRasika M Harshey
Jan 6, 2011·FEMS Microbiology Letters·Yang WangChengping Lu

❮ Previous
Next ❯

Citations

Nov 9, 2018·Journal of Clinical Microbiology·Aurélie MorandDidier Raoult
Nov 14, 2019·Current Pharmaceutical Biotechnology·Fazlurrahman KhanYoung-Mog Kim
Oct 24, 2020·Antibiotics·Virginio Cepas, Sara M Soto
Nov 24, 2020·Phytopathology·Yuan Zeng, Amy O Charkowski
May 28, 2021·Microbial Pathogenesis·Vélez María VictoriaPadola Nora Lía
Aug 26, 2021·Infection and Drug Resistance·Rasha El-MahdyRaghdaa Shrief

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
Electrophoresis
PCR

Software Mentioned

GraphPad

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.